As Macrogenics INC (MGNX) Valuation Declined, Ecor1 Capital LLC Lifted Stake

June 17, 2018 - By Ellis Scott

Investors sentiment increased to 1.79 in 2018 Q1. Its up 0.68, from 1.11 in 2017Q4. It is positive, as 13 investors sold MGNX shares while 25 reduced holdings. 30 funds opened positions while 38 raised stakes. 31.74 million shares or 12.30% more from 28.26 million shares in 2017Q4 were reported. Macquarie Gp owns 0% invested in MacroGenics, Inc. (NASDAQ:MGNX) for 80,000 shares. Deutsche Natl Bank Ag reported 188,755 shares. Citadel Ltd Liability Com holds 99,130 shares or 0% of its portfolio. Manufacturers Life Ins Com The reported 0% in MacroGenics, Inc. (NASDAQ:MGNX). Svcs Automobile Association accumulated 0% or 70,399 shares. Retail Bank Of Ny Mellon Corp reported 165,897 shares. Daiwa Gru Inc owns 0% invested in MacroGenics, Inc. (NASDAQ:MGNX) for 203 shares. State Board Of Administration Of Florida Retirement Systems owns 17,667 shares for 0% of their portfolio. Granahan Investment Mgmt Ma invested in 0.4% or 219,264 shares. Victory Management owns 176,600 shares. Keybank National Association Oh has invested 0% in MacroGenics, Inc. (NASDAQ:MGNX). Ameriprise Incorporated reported 0% of its portfolio in MacroGenics, Inc. (NASDAQ:MGNX). State Of Wisconsin Board holds 25,000 shares or 0% of its portfolio. Clearbridge Invests Limited Co, New York-based fund reported 3,985 shares. Citigroup, New York-based fund reported 13,564 shares.

Since January 16, 2018, it had 0 insider buys, and 7 insider sales for $1.10 million activity. Shares for $100,000 were sold by Wigginton Jon Marc. On Monday, March 5 the insider Karrels James sold $155,000. On Friday, March 2 Risser Eric Blasius sold $120,000 worth of MacroGenics, Inc. (NASDAQ:MGNX) or 4,000 shares.

Ecor1 Capital Llc increased its stake in Macrogenics Inc (MGNX) by 27.16% based on its latest 2018Q1 regulatory filing with the SEC. Ecor1 Capital Llc bought 309,812 shares as the company’s stock declined 7.73% with the market. The institutional investor held 1.45 million shares of the health care company at the end of 2018Q1, valued at $36.50M, up from 1.14 million at the end of the previous reported quarter. Ecor1 Capital Llc who had been investing in Macrogenics Inc for a number of months, seems to be bullish on the $949.13 million market cap company. The stock decreased 0.04% or $0.01 during the last trading session, reaching $22.49. About 246,353 shares traded. MacroGenics, Inc. (NASDAQ:MGNX) has risen 19.62% since June 17, 2017 and is uptrending. It has outperformed by 7.05% the S&P500.

More recent MacroGenics, Inc. (NASDAQ:MGNX) news were published by: Benzinga.com which released: “The Week Ahead In Biotech: ASCO Presentations Dominate The Headlines” on June 03, 2018. Also Nasdaq.com published the news titled: “New Research Coverage Highlights Materialise NV, MacroGenics, GasLog Partners LP, TCP Capital, NantHealth, and …” on June 06, 2018. Seekingalpha.com‘s news article titled: “Premarket analyst action – healthcare” with publication date: May 31, 2018 was also an interesting one.

MacroGenics, Inc. (NASDAQ:MGNX) Ratings Coverage

Among 6 analysts covering MacroGenics (NASDAQ:MGNX), 5 have Buy rating, 0 Sell and 1 Hold. Therefore 83% are positive. MacroGenics had 6 analyst reports since January 19, 2018 according to SRatingsIntel. The stock of MacroGenics, Inc. (NASDAQ:MGNX) earned “Buy” rating by BTIG Research on Friday, January 19. The firm earned “Equal-Weight” rating on Wednesday, March 14 by Morgan Stanley. The firm has “Buy” rating by SunTrust given on Tuesday, January 23. The company was initiated on Friday, April 6 by Leerink Swann.

MacroGenics, Inc. (NASDAQ:MGNX) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: